JP2012500815A - 抗ｃｄ５抗体 - Google Patents

抗ｃｄ５抗体 Download PDF

Info

Publication number
JP2012500815A
JP2012500815A JP2011524187A JP2011524187A JP2012500815A JP 2012500815 A JP2012500815 A JP 2012500815A JP 2011524187 A JP2011524187 A JP 2011524187A JP 2011524187 A JP2011524187 A JP 2011524187A JP 2012500815 A JP2012500815 A JP 2012500815A
Authority
JP
Japan
Prior art keywords
antibody
antibodies
composition according
antibody composition
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011524187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500815A5 (OSRAM
Inventor
ヨセフィネ・エル・コー・クリトゴー
チャールズ・パイク
ミッケル・ワンダール・ペダーセン
クラウス・ケーフェーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of JP2012500815A publication Critical patent/JP2012500815A/ja
Publication of JP2012500815A5 publication Critical patent/JP2012500815A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011524187A 2008-08-29 2009-08-28 抗ｃｄ５抗体 Withdrawn JP2012500815A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200801191 2008-08-29
DKPA200801191 2008-08-29
US9370008P 2008-09-02 2008-09-02
US61/093,700 2008-09-02
PCT/DK2009/050218 WO2010022737A1 (en) 2008-08-29 2009-08-28 Anti-cd5 antibodies

Publications (2)

Publication Number Publication Date
JP2012500815A true JP2012500815A (ja) 2012-01-12
JP2012500815A5 JP2012500815A5 (OSRAM) 2012-10-11

Family

ID=40677719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011524187A Withdrawn JP2012500815A (ja) 2008-08-29 2009-08-28 抗ｃｄ５抗体

Country Status (15)

Country Link
US (1) US20110250203A1 (OSRAM)
EP (1) EP2328932A1 (OSRAM)
JP (1) JP2012500815A (OSRAM)
KR (1) KR20110050541A (OSRAM)
CN (1) CN102137873A (OSRAM)
AU (1) AU2009287164A1 (OSRAM)
BR (1) BRPI0917148A2 (OSRAM)
CA (1) CA2735279A1 (OSRAM)
IL (1) IL209975A0 (OSRAM)
MX (1) MX2011000970A (OSRAM)
NZ (1) NZ591153A (OSRAM)
RU (1) RU2011111640A (OSRAM)
TW (1) TW201011045A (OSRAM)
WO (1) WO2010022737A1 (OSRAM)
ZA (1) ZA201100300B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024028902A (ja) * 2018-04-18 2024-03-05 バイオマジソン・インコーポレイテッド ワクチン製剤の効力を特徴付けるための細胞バンク

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520173A (ja) 2010-02-18 2013-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαｖβ８中和抗体
WO2012122514A1 (en) * 2011-03-09 2012-09-13 Centrose, Llc Extracellular targeted drug conjugates
WO2013023162A2 (en) * 2011-08-10 2013-02-14 Genus Oncology, Llc Anti-muc1 antibodies for cancer diagnostics
MX350335B (es) 2011-08-17 2017-09-04 Univ California Anticuerpos que enlazan alfa-v beta-8 integrina.
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN102786595B (zh) * 2012-08-03 2014-04-23 无锡傲锐东源生物科技有限公司 抗cd5蛋白单克隆抗体及其用途
US9708404B2 (en) 2012-12-21 2017-07-18 Seattle Genetics, Inc. Anti-NTB-A antibodies and related compositions and methods
ES2871816T3 (es) * 2012-12-27 2021-11-02 Sanofi Sa Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
DK2943511T3 (da) 2013-01-14 2019-10-21 Xencor Inc Nye heterodimeriske proteiner
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2015123777A1 (en) * 2014-02-19 2015-08-27 Cangene Corporation Methods of modulating an immune response
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107406512A (zh) 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
KR102689285B1 (ko) 2014-11-26 2024-07-31 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10786549B2 (en) 2015-04-23 2020-09-29 Baylor College Of Medicine CD5 chimeric antigen receptor for adoptive T cell therapy
WO2017214285A1 (en) * 2016-06-07 2017-12-14 Eynav Klechevsky Detection of cd5 and methods and compositions for modulating cd5
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
MY199683A (en) * 2016-09-16 2023-11-16 Shanghai Henlius Biotech Inc Anti-pd-1 antibodies
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
BR112020010662A2 (pt) 2017-11-29 2020-11-10 Magenta Therapeutics, Inc. composições e métodos para a depleção de células cd5+
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CN121059792A (zh) 2018-12-19 2025-12-05 宾夕法尼亚大学董事会 Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途
EP3947406A4 (en) 2019-04-05 2022-12-28 Academia Sinica SIALIDASE RESISTANT SACCHARIDE, METHOD FOR PRODUCTION AND USE
KR20220003572A (ko) 2019-04-24 2022-01-10 하이델베르크 파마 리서치 게엠베하 아마톡신 항체-약물 결합체 및 이의 용도
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
GB2628935B (en) 2019-09-03 2025-03-05 Myeloid Therapeutics Inc Methods and compositions for genomic integration
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
KR20230038416A (ko) 2020-05-08 2023-03-20 아카데미아 시니카 키메릭 인플루엔자 백신
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20230340089A1 (en) * 2020-05-14 2023-10-26 City Of Hope Smc1a antibodies and uses thereof
EP3915641A1 (en) * 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
US20230340141A1 (en) * 2020-08-21 2023-10-26 City Of Hope Anti-cd5 antibody compositions and uses thereof
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
CN116801905A (zh) * 2020-12-17 2023-09-22 先声再明医药有限公司 Cd5抗体及其应用
US20240050568A1 (en) * 2021-01-12 2024-02-15 Nanjing IASO Biotechnology Co., Ltd. Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
WO2022192403A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
MX2023000578A (es) 2021-04-12 2023-04-26 Academia Sinica Vacuna mejorada contra el coronavirus.
EP4332118A1 (en) * 2021-04-29 2024-03-06 Korea Research Institute of Bioscience and Biotechnology Novel anti-cd5 chimeric antigen receptor and immune cell expressing same
AU2022272235A1 (en) 2021-05-11 2023-12-21 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CN113105547B (zh) * 2021-05-18 2022-04-08 福州迈新生物技术开发有限公司 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US12077597B2 (en) 2021-11-24 2024-09-03 International-Drug-Development-Biotech Anti-CD5 antibodies and methods of use thereof
US20230279080A1 (en) * 2021-12-27 2023-09-07 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
WO2024039683A1 (en) * 2022-08-15 2024-02-22 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
TW202502301A (zh) 2023-04-08 2025-01-16 磐石醫藥生技股份有限公司 透過聚合物囊泡進行標的遞送之方法及組合物
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024258967A1 (en) * 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312916C2 (de) * 1993-04-14 1995-03-23 Fresenius Ag Arzneimittel zur Behandlung von Immunreaktionen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024028902A (ja) * 2018-04-18 2024-03-05 バイオマジソン・インコーポレイテッド ワクチン製剤の効力を特徴付けるための細胞バンク

Also Published As

Publication number Publication date
NZ591153A (en) 2012-12-21
RU2011111640A (ru) 2012-10-10
US20110250203A1 (en) 2011-10-13
EP2328932A1 (en) 2011-06-08
TW201011045A (en) 2010-03-16
MX2011000970A (es) 2011-03-15
ZA201100300B (en) 2012-01-25
KR20110050541A (ko) 2011-05-13
CN102137873A (zh) 2011-07-27
WO2010022737A1 (en) 2010-03-04
AU2009287164A1 (en) 2010-03-04
CA2735279A1 (en) 2010-03-04
IL209975A0 (en) 2011-02-28
BRPI0917148A2 (pt) 2015-12-01

Similar Documents

Publication Publication Date Title
JP2012500815A (ja) 抗ｃｄ５抗体
EP3380196B1 (en) Heterodimeric antibodies that bind cd3 and cd38
KR101805140B1 (ko) 재조합 항-표피 성장 인자 수용체 항체 조성물
CN112703013B (zh) Cd3抗原结合片段及其应用
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
BR112019016204A2 (pt) anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
CN113563470B (zh) 结合tigit抗原的抗体及其制备方法与应用
CN107365385A (zh) 抗cd38抗体
EP2925782A2 (en) Anti-cd47 antibodies and methods of use thereof
TW201141519A (en) Anti-HER2 antibodies and compositions
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
EP4588524A2 (en) Anti-tigit and anti-pvrig in monotherapy and combination treatments
KR20210114920A (ko) 인간 및 원숭이 cd38 항원에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
WO2021013061A1 (zh) 一种人源化抗vegfr2抗体及其应用
US20070136826A1 (en) Anti-mouse CD20 antibodies and uses thereof
JP2023532248A (ja) 免疫関連疾患のためのｔｉｇｉｔに対するヒトモノクローナル抗体
RU2770620C1 (ru) Связывающие молекулы, вызывающие клеточную активацию
EP3915641A1 (en) Anti-cd5 antibodies and methods of use thereof
KR102661163B1 (ko) 항 pd-1 항체 및 그의 용도
JP2023513059A (ja) 抗ミューラー管ホルモン受容体２抗体及び使用方法
KR20230145542A (ko) Tgf-베타-rii 결합 단백질
AU2020257053B2 (en) Cell engaging binding molecules
CN116829590A (zh) Anti-pd-1抗体及其用途
US12077597B2 (en) Anti-CD5 antibodies and methods of use thereof
JP7384668B2 (ja) 細胞傷害性ｔ細胞枯渇用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120827

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130729